WASHINGTON (AP) — A House lawmaker says former Turing Pharmaceuticals CEO Martin Shkreli, reviled for price hiking, has not made legal arrangements to appear before Congress next week, despite receiving a subpoena. House lawmakers want to question Shkreli about his decision to hike the price of Daraprim, the only approved drug for a rare and sometimes deadly parasitic infection, by 5,000 percent.